Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

该研究公司强调了安进的强劲销售表现，特别是其Evenity和Imdelltra产品，这些表现使Cantor Fitzgerald模型中的更高估计得到了证实。这一表现促成了安进稳健的股息状况，该公司已连续15年保持股息支付，目前收益率为3.3%。

Investing.com - 伯恩斯坦法兴集团周四将安进 (NASDAQ:AMGN)的目标价从350.00美元下调至335.00美元，同时维持对该股票的"优于大市"评级。根据 InvestingPro 数据，该股票目前的市盈率为23.5倍，分析师目标价范围从185美元到405美元不等。

汇通财经APP讯——市场消息显示，安进减肥药Maritide在第二阶段第一部分临床研究中呈现出平均减重20%的效果。 【免责声明】本文仅代表作者本人 ...

市场消息显示，安进减肥药Maritide在第二阶段第一部分临床研究中呈现出平均减重20%的效果。 _外汇动态报道 首页> 要闻中心> 正文 黄金、外汇、原油、期货多空提醒软件 2025-06-24 02:35:50 ...

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug MariTide, Street analysts are weighing in. And there's a theme: They want ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

MariTide: Weight Loss With Type 2 Diabetes (Amgen MariTide Update - 11/26/24) Study participants lowered their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52.

Wall Street began comparing and contrasting what’s available after Amgen Inc. rolled out phase II data with weight loss candidate Maritide – a disclosure that led shares of the biotech heavyweight ...

--Amgen today announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the ...